Q3 2017 Earnings Estimate for Nektar Therapeutics (NASDAQ:NKTR) Issued By William Blair

Nektar Therapeutics (NASDAQ:NKTR) – Equities research analysts at William Blair raised their Q3 2017 earnings estimates for shares of Nektar Therapeutics in a research report issued on Tuesday. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn $0.15 per share for the quarter, up from their prior forecast of ($0.35). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Nektar Therapeutics’ Q4 2017 earnings at ($0.38) EPS, FY2017 earnings at ($1.03) EPS, Q1 2018 earnings at ($0.38) EPS, Q2 2018 earnings at ($0.37) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.37) EPS, FY2018 earnings at ($1.49) EPS and FY2019 earnings at ($1.47) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. The firm had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.36) earnings per share.

TRADEMARK VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/2801199/q3-2017-earnings-estimate-for-nektar-therapeutics-nasdaqnktr-issued-by-william-blair.html.

Several other analysts have also issued reports on NKTR. Jefferies Group LLC set a $25.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a report on Saturday, April 22nd. Aegis reiterated a “buy” rating and set a $27.00 price objective on shares of Nektar Therapeutics in a report on Wednesday, May 10th. Roth Capital set a $31.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 11th. ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BidaskClub upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Nektar Therapeutics presently has an average rating of “Buy” and a consensus target price of $26.78.

Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at 17.95 on Friday. The firm’s market capitalization is $2.79 billion. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $24.88. The firm’s 50-day moving average price is $20.60 and its 200 day moving average price is $18.28.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 8,388 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $19.55, for a total transaction of $163,985.40. Following the transaction, the chief executive officer now directly owns 160,884 shares in the company, valued at $3,145,282.20. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Ivan P. Gergel sold 54,920 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $21.10, for a total value of $1,158,812.00. Following the transaction, the senior vice president now owns 98,492 shares in the company, valued at $2,078,181.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 159,803 shares of company stock worth $3,328,247. Corporate insiders own 6.10% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Flinton Capital Management LLC increased its stake in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares in the last quarter. First Trust Advisors LP increased its stake in shares of Nektar Therapeutics by 8.0% in the first quarter. First Trust Advisors LP now owns 2,249,950 shares of the biopharmaceutical company’s stock valued at $52,806,000 after buying an additional 166,521 shares in the last quarter. Great West Life Assurance Co. Can increased its stake in shares of Nektar Therapeutics by 7.0% in the first quarter. Great West Life Assurance Co. Can now owns 213,944 shares of the biopharmaceutical company’s stock valued at $5,019,000 after buying an additional 13,956 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in shares of Nektar Therapeutics by 16.9% in the first quarter. Tocqueville Asset Management L.P. now owns 234,402 shares of the biopharmaceutical company’s stock valued at $5,501,000 after buying an additional 33,850 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of Nektar Therapeutics by 7.4% in the first quarter. Wells Fargo & Company MN now owns 207,320 shares of the biopharmaceutical company’s stock valued at $4,866,000 after buying an additional 14,202 shares in the last quarter. 94.09% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.